NASDAQ:SERA Sera Prognostics (SERA) Stock Price, News & Analysis $1.94 +0.03 (+1.30%) As of 10:12 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Sera Prognostics Stock (NASDAQ:SERA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sera Prognostics alerts:Sign Up Key Stats Today's Range$1.90▼$1.9550-Day Range$1.59▼$2.2952-Week Range$1.56▼$3.95Volume858 shsAverage Volume54,395 shsMarket Capitalization$76.17 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingModerate Buy Company Overview Sera Prognostics, Inc. is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery. Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test. The company has secured relevant regulatory clearances and reimbursement pathways, and continues to explore additional clinical applications for its proteomic platform. Collaborative efforts with academic institutions and health systems support ongoing studies aimed at demonstrating the test’s utility in diverse patient populations. Headquartered in Salt Lake City, Utah, Sera Prognostics is led by President and Chief Executive Officer Zachary Carr, who brings experience in commercializing diagnostic technologies. Under his leadership, the company has built a multidisciplinary team of professionals in molecular diagnostics, clinical operations, regulatory affairs, and market access. Sera Prognostics remains dedicated to advancing maternal–fetal health and expanding its footprint through partnerships with healthcare organizations and research sponsors.AI Generated. May Contain Errors. Read More Sera Prognostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreSERA MarketRank™: Sera Prognostics scored higher than 66% of companies evaluated by MarketBeat, and ranked 286th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingSera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialSera Prognostics has a consensus price target of $5.50, representing about 186.5% upside from its current price of $1.92.Amount of Analyst CoverageSera Prognostics has only been the subject of 2 research reports in the past 90 days.Read more about Sera Prognostics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sera Prognostics are expected to grow in the coming year, from ($0.58) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sera Prognostics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.76% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 6.45.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 1.02%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment0.93 News SentimentSera Prognostics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sera Prognostics this week, compared to 2 articles on an average week. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,840.00 in company stock.Percentage Held by Insiders11.30% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sera Prognostics' insider trading history. Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SERA Stock News HeadlinesPRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CAREJuly 9, 2026 | prnewswire.comSERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORSJune 30, 2026 | prnewswire.comConfirm Your Name Before the Letter Goes OutAmericans who believe in real retirement protection are adding their names to a statement going out to Washington and Wall Street. It's a message that people are fed up with inflation and the erosion of their savings. President Trump took a stand on protecting American wealth. Now you can add your voice while also learning how to move part of your IRA or 401(k) into physical gold and silver, tax and penalty free.July 14 at 1:00 AM | American Alternative (Ad)SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTHJune 24, 2026 | prnewswire.comSERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCYJune 23, 2026 | prnewswire.comSera Prognostics Holds 2026 Annual Stockholders MeetingJune 4, 2026 | tipranks.comSERA PROGNOSTICS ANNOUNCES BOARD TRANSITIONJune 1, 2026 | prnewswire.comSera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2026 Financial ResultsMay 9, 2026 | finanznachrichten.deSee More Headlines SERA Stock Analysis - Frequently Asked Questions How have SERA shares performed this year? Sera Prognostics' stock was trading at $2.95 at the beginning of the year. Since then, SERA stock has decreased by 34.9% and is now trading at $1.92. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative trailing twelve-month return on equity of 41.02%. Read the conference call transcript. When did Sera Prognostics IPO? Sera Prognostics (SERA) raised $75 million in an initial public offering (IPO) on Wednesday, July 14th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sera Prognostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sera Prognostics investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD). Company Calendar Last Earnings5/06/2026Today7/14/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:SERA CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees120Year Founded2008Price Target and Rating Average Price Target for Sera Prognostics$5.50 High Price Target$6.00 Low Price Target$5.00 Potential Upside/Downside+182.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.93 million Net Margins-56,385.97% Pretax Margin-56,385.96% Return on Equity-41.02% Return on Assets-30.95% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio2.12 Sales & Book Value Annual Sales$80 thousand Price / Sales952.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book1.00Miscellaneous Outstanding Shares39,160,000Free Float34,734,000Market Cap$76.17 million OptionableOptionable Beta0.97 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:SERA) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersThe $5 company SpaceX can’t survive withoutThe investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...Traders Agency | SponsoredConfirm Your Name Before the Letter Goes OutAmericans who believe in real retirement protection are adding their names to a statement going out to Washing...American Alternative | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sera Prognostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SERA Stock Alerts